达格列净在血液透析与腹膜透析患者中的药代动力学特性
本前瞻性单中心开放标签试验比较了透析肾衰竭患者与肾功能正常的2型糖尿病对照者口服达格列净10 mg后的药代动力学与安全性。肾衰竭组达格列净峰浓度为117 ng/ml,对照组为97.6 ng/ml,两组蓄积比分别为26.7%和9.5%,透析液回收药物占给药剂量0.10%,两组均未报告严重不良事件。
要点
- 透析肾衰竭患者达格列净峰浓度117 ng/ml,对照97.6 ng/ml。
- 肾衰竭组蓄积比26.7%,对照组9.5%,提示无蓄积。
- 透析液回收药物占给药剂量0.10%,达格列净可轻度透析清除。
核心结论
- 在透析肾衰竭患者中,达格列净耐受良好,可轻度透析清除,且具有无蓄积的药代动力学特性。
研究设计与样本
- 前瞻性、单中心、开放标签试验(ClinicalTrials.gov注册号NCT05343078),比较规律透析的肾衰竭患者与年龄性别匹配、肾功能正常的2型糖尿病对照者。
- 两组均在达格列净10 mg给药后每30分钟采集外周血共4小时并于48小时后再次采集,肾衰竭组于透析开始前即刻给药。
- 该方案先在未用过药的患者中实施,再在每日一次达格列净连续6剂后重复,以评估药物是否蓄积。
主要发现
- 肾衰竭组达格列净峰浓度(C max)为117 ng/ml,对照组为97.6 ng/ml。
- 肾衰竭组蓄积比为26.7%,对照组为9.5%。
- 两组均未报告严重不良事件。
- 透析液回收的达格列净占给药剂量的0.10%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors attenuate incident cardiovascular outcomes, irrespective of baseline GFR, in conservatively managed CKD. As this condition inexorably progresses to demanding KRT, drug withdrawal is supported by the current lack of evidence of safety of SGLT2 inhibitors in dialysis. METHODS: This study was a prospective, single-center, open-label trial ( ClinicalTrials.gov identifier: NCT05343078 ) aimed at assessing the pharmacokinetic properties and safety of dapagliflozin in patients with kidney failure on regular dialysis regimens compared with those with type 2 diabetes and age- and sex-matched controls with normal kidney function. Peripheral blood samples were collected from both groups every 30 minutes for 4 hours and again after 48 hours after ingestion of dapagliflozin 10 mg, which occurred immediately before dialysis session initiation in the kidney failure group. This protocol occurred in drug-naïve patients and again after six daily doses of dapagliflozin to assess whether the drug had accumulated. The plasma and dialysate levels of dapagliflozin at each time point were determined by liquid chromatography and used to calculate pharmacokinetics parameters (peak concentration [C max ] and area under the plasma concentration-versus-time curve) for each participant. RESULTS: Dapagliflozin C max was 117 and 97.6 ng/ml in the kidney failure and control groups, respectively, whereas the corresponding accumulation ratios were 26.7% and 9.5%. No serious adverse events were reported for either group. Dapagliflozin recovered from dialysate corresponded to 0.10% of the administered dose. CONCLUSIONS: In patients with kidney failure on dialysis, dapagliflozin was well tolerated, was slightly dialyzable, and had nonaccumulating pharmacokinetic properties. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients (DARE-ESKD 1), NCT05343078.
引用
- Barreto J, Borges C, Rodrigues TB, et al. Pharmacokinetic Properties of Dapagliflozin in Hemodialysis and Peritoneal Dialysis Patients. Clin J Am Soc Nephrol. 2023. PMID: 37227937. doi:10.2215/CJN.0000000000000196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。